Company news
Firebrick Pharma Limited (ASX:FRE) news
Firebrick Pharma Limited news releases on 6ix. Latest, May 31, 2023: Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Press releases — page 2
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
May 30, 2023
Firebrick Raises $1 million via Placement
April 30, 2023
March 2023 Quarterly Activity Report & Appendix 4C
April 19, 2023
Nasodine COVID-19 Trial Concludes Recruitment
April 3, 2023
Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
March 20, 2023
FRE files EU Paediatric Investigation Plan for Nasodine
February 20, 2023
Appendix 4D & Half Yearly Report and Accounts
February 17, 2023
December 2022 Quarterly Activity Report & Appendix 4C
January 18, 2023
Nasodine Composition Patent Accepted in Australia
November 13, 2022
Firebrick Receives $1.08m R&D Tax Incentive
November 8, 2022
September 2022 Quarterly Activity Report & Appendix 4C
October 31, 2022
Appendix 4E & Annual Report
August 23, 2022
June 2022 Quarterly Activity Report & Appendix 4C
July 28, 2022
Outcome of s60 appeal for Nasodine and next steps
July 7, 2022
Firebrick starts Phase 3 common cold trial of Nasodine
May 3, 2022
March 2022 Quarterly Activity Report & Appendix 4C
April 26, 2022
Firebrick starts COVID-19 trial of Nasodine
April 26, 2022
31 December Interim Financial Report & Appendix 4D
February 11, 2022